Roberto Hofmann is an Analyst at Forbion, which he joined in 2025. Since then, he has been involved across both Forbion's Ventures and Growth strategies and is currently board observer at Elevara Medicines, and an early stealth company.

Prior to Forbion, he co-founded a stealth biotech company in the protein degradation space in collaboration with TSL Ventures. Roberto holds a PhD in Molecular Biology from the University of Cambridge and a from University College London. Alongside his studies, he gained experience at McKinsey & Company and Equitas Capital.